Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
8MgzV2pFr4DS0K6q
Listen
